INTRODUCTION

The major function of the circulatory system is to deliver oxygen and nutrients to the cells throughout the body (Del Re et al., 2019; Kaelin et al., 2016). An insufficient blood supply, if not corrected in time, leads to depletion of oxygen and nutrients to vital organs, resulting in organ failure and death. As we know, coronary artery disease (CAD) and stroke caused by ischemia, a sudden and severe blockage of coronary or brain arteries, are one of the most common causes of death worldwide (Khera & Kathiresan, 2017; Vogel et al., 2019). Every year, an estimation of 720,000 people in the United States is hospitalized with acute coronary syndrome or has fatal coronary heart disease events (Rodriguez & Harrington, 2021).

Myocardial infarction (MI) is the most severe manifestation of CAD. Approximately every 40 s, an individual is hospitalized due to myocardial infarction (van Diepen et al., 2017). Reperfusion strategies, including angiography and percutaneous coronary intervention (PCI), are the widely used for CAD and MI patients (Thiele et al., 2018). Also, artery bypass graft surgery is considered to treat MI patients with a large myocardial area at jeopardy or cardiogenic shock (Solo et al., 2019). However, these therapeutic strategies are not suitable for some elder patients with diffuse myocardial infarction. To meet the needs...
for those patients, therapeutic angiogenesis has been proposed as an attractive novel strategy for CAD and MI treatment. It is a combined utilization of chemicals and angiogenic factors to enhance neovascularization and growth of collateral blood vessels, which act as endogenous bypass conduits to increase tissue perfusion and provide oxygen and nutrients in the ischemic area. Thus, it is an emerged demand to identify novel and effective angiogenic compound for MI treatment.

Dioscin, a glucoside saponin, is one natural product identified from certain medicinal plants such as Dioscoreazingiberensis Wright and Dioscoreamakinoii Makino (Tao et al., 2018). Recent studies suggest that Dioscin lowers the lipid levels and represses the inflammatory response, showing the hepatoprotective effects (Yao et al., 2018; Zhang et al., 2017). Additionally, it has been widely used in clinics as CAD treatment for many years in China. However, the mechanism underlying the protective effect of Dioscin on the infarcted hearts needs to be elucidated.

Recently, emerging data indicate that long noncoding RNAs (LncRNA, >200 nucleotides in length), a major population of transcriptome, play critical roles in the physiology and pathophysiology of cardiovascular diseases by distinct mechanisms (Ransohoff et al., 2018). Hypoxia-induced endothelial lncRNA MANTIS (metastasis-associated lung adenocarcinoma transcript 1) identified in the antisense strand of the intron of Annexin A4, a calcium and phospholipid binding protein, is expressed in different cellular types. MANTIS silencing causes the endothelial dysfunction, impairing sprouting and tube formation, and attenuating endothelial migration. MANTIS is required for endothelial cells proliferation, neonatal retina vascularization, and vascular growth in vivo after hindlimb ischemia (Cremer et al., 2019). A key function of IncRNA MANTIS is by interacting and combining with brahma related gene-1 (BRG1), to regulate gene transcription, including SRY (sex determining region Y)-box 18 (SOX18), mothers against decapentaplegic homologue 6 (SMAD6), and nuclear receptor subfamily 2 group F member 2 (COUP-TFI), which are important for angiogenesis in endothelial cells. Although lncRNAs have been proven crucial in ischemic diseases, whether lncRNAs are regulated by Dioscin remains unclear in myocardial infarction.

Here, we demonstrate that a natural product Dioscin alleviates hypoxic-caused cardiac dysfunction in mouse model of myocardial infarction via up-regulating the level of lncRNA MANTIS. We show that Dioscin increases IncRNA MANTIS expression, promoting the complex formation of MANTIS and BRG1, elevating the expression of SOX18, SMAD6, and COUP-TFI, resulting in promoted angiogenesis in myocardial infarction.

2 | RESULTS

2.1 | Dioscin attenuates cardiac dysfunction in mouse model of myocardial infarction

To explore the effects of Dioscin in response to MI, we applied Dioscin as a therapeutic treatment in mouse MI model. Echocardiography showed that Dioscin significantly improved cardiac functions after MI (Figure 1a). Ejection fraction (EF), a vital parameter for cardiac function, was improved after Dioscin treatment in infarcted hearts, compared to vehicle treatment (Figure 1b). Similarly, significant improvement was observed for fraction shortening (FS) with Dioscin administration (Figure 1b). Additionally, declination of the left ventricular end-diastolic diameters (LVEDD) and left ventricular end-systolic diameters (LVESD) in response to MI was dramatically rescued by Dioscin in mice suffered with MI, indicating Dioscin could help to maintain cardiac structure in infarcted hearts (Figure 1c).

Dioscin repressed the increase of heart size caused by myocardial infarction (Figure 1d). As shown in Figure 1e,f, MI caused the increase of the ratios of heart weight (HW) to body weight (BW) or tibia length (TL). However, this hypertrophic tendency was alleviated by Dioscin administration. Additionally, the mRNA levels of biomarkers for heart failure, including Anp, Bnp, and β-Mhc, were declined after MI with Dioscin treatment (Figure 1g). These findings suggest that Dioscin can rescue cardiac function and delay the progress of heart failure caused by myocardial infarction.

2.2 | Dioscin promotes angiogenesis in mice after myocardial infarction

To further confirm whether Dioscin attenuates the cardiac dysfunction after MI, we explored the therapeutic effect of Dioscin in the infarcted hearts. Administration of Dioscin significantly reduced the size of cardiac fibrosis in response to MI, compared to vehicle (Figure 2a). The number of CD31-positive cells was increased in Dioscin-treated infarcted hearts compared with vehicle treatment, indicating that Dioscin promoted angiogenesis in mouse model of MI (Figure 2b). What is more, the ratio for Bcl2/Box mRNAs was declined in infarcted hearts, and this reduction was blocked by Dioscin (Figure 2c). These data indicate that Dioscin enhances angiogenesis and alleviates cardiac apoptosis and fibrosis in response to infarction.

2.3 | Dioscin enhances angiogenesis in hypoxic endothelial cells

Although angiogenesis is associated with Dioscin treatment in mouse model of MI, whether Dioscin promotes angiogenesis or not is uncovered. In vitro experiments, human umbilical vein endothelial cells (HUVECs) were incubated with cobalt (II) chloride (CoCl2) to mimic hypoxic condition. Under basic condition, Dioscin did not affect the endothelial proliferation (Figure 3a). Notably, in hypoxic condition, the number of CoCl2-cultured endothelial cells was increased, accompanying with the increased doses of Dioscin (Figure 3a). In wound healing assays, Dioscin promoted endothelial cell migration in dose-dependent manner under hypoxic condition (Figure 3b). Consistently with the results from wound healing assays, in response to hypoxia, Dioscin induced more ECs migrated across the membrane in transwell migration.
assays (Figure 3c). We also performed tube formation assays, showing that Dioscin increased the numbers for capillary tubes and branching points in hypoxic condition (Figure 3d). These data suggest that Dioscin promotes angiogenesis in hypoxic endothelial cells.

2.4 Increase for lncRNA MANTIS is associated with Dioscin treatment

As lncRNAs are involved in the development of cardiovascular diseases, we examined whether angiogenesis is involved in regulating the expression of lncRNAs that were reported in endothelial cells. We profiled 50 lncRNAs, reported which play a vital role in endothelial cells, in hypoxic HUVECs with/without Dioscin treatment using real-time PCR assays (Figure 4a). As depicted in Figure 4a, the change for lncRNA MANTIS expression was highest after Dioscin treatment. To confirm these results, the levels for MANTIS were detected in different doses of Dioscin, showing the expression level of MANTIS was positively correlated with the doses of Dioscin both in infarcted heart tissue and hypoxic HUVECs (Figure 4b,c).

2.5 Dioscin induces angiogenesis via up-regulation of lncRNA MANTIS in hypoxic endothelial cells

In order to identify whether Dioscin promotes angiogenesis via MANTIS or not, we detected angiogenesis after MANTIS knockdown in Dioscin-treated HUVECs. First, we detected the efficiency of siMANTIS, which decreased about 70% in mRNA level (Figure 4d). In the scratch assays, although Dioscin promoted the migration of hypoxic endothelial cells into the wounded areas, deficiency of MANTIS abolished endothelial migration caused by Dioscin (Figure 4e). Additionally, in transwell migration assays, Dioscin increased the numbers of ECs that migrated across the membranes, and this increase was suppressed after MANTIS knockdown (Figure 4f).
Consistently, the capillary tube formation mediated by Dioscin was alleviated by the reduction of MANTIS (Figure 4g). Taken together, these results suggest that Dioscin mediates the effect of angiogenesis via up-regulation of MANTIS.

2.6 Dioscin accelerates the formation of MANTIS and BRG1 complex

It was reported that MANTIS can interact with BRG1, regulating angiogenic gene expression. To assess whether Dioscin regulates an interaction of BRG1/MANTIS complex for angiogenesis or not, we performed RNA chromatin immunoprecipitation assays (RNA ChIP) in hypoxic condition. In HUVECs, hypoxia promoted the formation of BRG1 and MANTIS, while Dioscin accelerated this complex formation (Figure 5a).

To further verify Dioscin affects angiogenesis via the complex of BRG1 and MANTIS, we measured the expression levels for BRG1 downstream, such as SOX18, SMAD6, and COUP-TFII. The increase for these genes expression was observed after Dioscin treatment. However, MANTIS knockdown repressed the increase for SOX18, SMAD6, and COUP-TFII expression (Figure 5b–d). Furthermore, the co-staining for CD31 and BRG1 strongly demonstrated that the expression of BRG1 was significant enhanced in endothelial cells after Dioscin treatment in MI model (Figure 5e). These data indicate that Dioscin enhances angiogenesis via the formation of MANTIS and BRG1 complex (Figure 5f).

3 DISCUSSION

In this study, we demonstrated that Dioscin efficiently rescues cardiac dysfunction in response to myocardial infarction. Interestingly, cardioprotective Dioscin promotes the increase of IncRNA MANTIS, forming the complex of MANTIS and BRG1, resulting in tube formation and angiogenesis, alleviating cardiac fibrosis and apoptosis. Our results suggest that Dioscin is a novel candidate for therapeutic strategy for MI.

Dioscin has a potential effect of angiogenesis and anti-apoptosis on infarcted hearts. Currently, United States Food and Drug Administration (FDA) has not approved any therapeutic angiogenic strategies for CAD/MI treatment (Bergers & Hanahan, 2008; Fischer et al., 2008). However, new angiogenic factors and chemicals are urgent to be identified and applied in clinics. In our study, Dioscin is considered as a potential and effective therapeutic nature product for infarcted hearts, rescuing the cardiac function in mouse model of MI via promoting of angiogenesis. Additionally, the cardiac fibrosis and apoptosis were alleviated by Dioscin in infarcted hearts.
Moreover, Tao et al demonstrated that Dioscin alleviates cerebral inflammation via HMGB-1/TLR-4 signaling pathway after middle cerebral artery occlusion in mouse, preventing cellular apoptosis (Tao et al., 2015). Herein, the apoptotic cells were suppressed by Dioscin in MI mouse model, reflecting from the reduction of Bax and the augment of Bcl2. It is possible that the effect of Dioscin-caused anti-apoptosis is resulted from the promoted angiogenesis in ischemic hearts. Once angiogenesis occurs, the supply of nutrition and oxygen is recovered in the ischemic tissues, leading to suppress apoptosis (Esposito et al., 2018; Lin et al., 2018). Thus, Dioscin is a potent and promising candidate of therapeutic strategy for ischemic diseases.

Another major novelty of this work is identified that Dioscin promotes angiogenesis via up-regulation of IncRNA MANTIS. MANTIS silencing leads to the endothelial dysfunction, impairing sprouting and tube formation, and attenuating endothelial migration (Zampetaki & Mayr, 2017). Down-regulation of angiogenesis-related genes was observed after MANTIS knockdown. Mechanistically, in endothelial cells, MANTIS has been found to act as a scaffolding IncRNA within a chromatin remodeling complex and up-regulate endothelial genes, including SOX18, SMAD6, and COUP-TFII transcription by enabling pol II binding to the transcription start sites (Michalik et al., 2014; Yan et al., 2015). It is of high interest that Dioscin increases the levels of MANTIS both in MI mouse model and hypoxic endothelial cells, accelerating endothelial proliferation and migration in ischemic/hypoxic conditions, resulting in therapeutic angiogenesis.

In summary, we show that Dioscin has a good cardioprotective effect against myocardial infarction in mice via the up-regulation of IncRNA MANTIS, accelerating endothelial migration and angiogenesis, attenuating apoptosis and fibrosis, and resulting in alleviating cardiac dysfunction. Accordingly, Dioscin may serve as a novel treatment not only for myocardial infarction, but also for many other ischemic diseases.
and skin incision was closed by sutures. Mice with sham-operation then returned inside the chest. The chest wall was closed in layers, nentially with a 7–0 nonabsorbable surgical suture, and the heart was exteriorized out of the chest. The LAD coronary artery was ligated permanently in the second intercostal space, and the heart was then returned inside the chest. The chest wall was closed in layers, and skin incision was closed by sutures. Mice with sham-operation were subjected to the same surgical treatment, but the LAD was not ligated.

Dioscin (Diao group, Chengdu, China) was intragastric administration 1 day after ligation and continued until the mice were sacrificed 2 weeks. Mice in the control group received an equal volume of the solvent orally.

4 | MATERIALS AND METHODS

4.1 | Mouse model

Male C57BL/6 mice were unrestricted access to food and water and were housed in the controlled environment, with regulation of temperature (22 ± 1°C) and humidity (55%), a 12:12-h dark-light cycle. All animal experiments were carried out in accordance with the principles provided by the National Institute of Health Guideline and were approved by the Animal Care and Use Committee of Nanjing Medical University (IACUC-1912034).

Mouse model of MI was generated by ligation of the left anterior descending (LAD) as described previously with male mice at the age of 8–10 weeks (Lu et al., 2016). Briefly, the mice were anesthetized with isoflurane and then intubated with a fine polyethylene cannula containing 5% (v/v) fetal bovine serum (FBS) and EGM-2 Single Quots (Lonza, USA). The cells were cultured in the EGM medium containing 5% (v/v) fetal bovine serum (FBS) and EGM-2 Single Quots (Lonza, USA).

Human umbilical vein endothelial cells were transfected with siRNA using the electroporation P5 Primary Cell Nucleofector Kits (Lonza). The transfection efficiency of siRNA was determined by real-time RT-PCR analysis of a target gene. The sequences of siMANTIS: sense, 5′-AAA UGA AGC AGC CUU GUU GUC UGG G-3′; anti-sense, 5′-AAA UCU GAA GCG ACG UUC UGU UGG G-3′ (Genpharm, China).

FIGURE 4 Dioscin increases lncRNA MANTIS level in hypoxic endothelial cells. (a) The expression levels for lncRNAs were detected in Dioscin-treated hypoxic endothelial cells by using real-time PCR assays. (b) Dioscin promoted expression of MANTIS in endothelial cells. (c) Dioscin promoted expression of MANTIS in endothelial cells. (d) The efficiency of siMANTIS in endothelial cells. (e) MANTIS knockdown inhibited Dioscin-induced migration of ECs using scratch assays (scale bar: 500 μm). (f) Transfection of siRNA against MANTIS inhibited Dioscin-induced migration of ECs using transwell assays (scale bar: 200 μm). (g) MANTIS-specific siRNA inhibited Dioscin-induced tube formation of ECs (scale bar: 100 μm). Date were expressed as mean ± SEM. *p < 0.05 relative to Control; #p < 0.05 relative to CoCl2 with Vehicle; &p < 0.05 relative to CoCl2 with 1.25 mg/L Dioscin. [Corrections added on 30 June 2021 after first online publication: the 4th image in the first upper-lane in Figure 4g (DIO treatment with siMTS) was incorrect and also CoCl2 in the lower graph was incorrectly displayed as CoCl. These errors were corrected and revised figure was updated in this version.]
FIGURE 5 Dioscin enhances the complex formation between MANTIS and BRG1. (a) Chromatin Immunoprecipitation (CHIP) was performed to access the assembly of the MANTIS and BRG1 by Dioscin. (b) Real-time reverse transcription (RT-PCR) analysis was performed for SOX18 mRNA expression. (c) SMAD6 mRNA level was detected in Dioscin-treated endothelial cells using real-time PCR analysis. (d) Real-time PCR analysis for COUP-TFII mRNA expression. (e) Representative images of CD31 (red), BRG1 (green), and nucleus (blue) co-staining in endothelial cells in heart tissue after Sham and MI group (scar bar: 50 μm). (f) Schematic diagram showing the molecular signing pathway for Dioscin-induced angiogenesis. *p < 0.05 relative to siScr; #p < 0.05 relative to Vehicle

| Species | Name | Forward primer (5′→3′) | Reverse primer (5′→3′) |
|---------|------|------------------------|------------------------|
| Human   | SOX18 | CATGGTGTGGGCAAAGGAC   | GCCGGTACTTGAGTTGGG    |
| Human   | SMAD6 | CTCCTATACGGTACGCAGC   | GATGCCGAAGCCGATCTTG   |
| Human   | COUP-TFII | CGCCCTATAGGAACATACCG | TCCACATGGGTCATCAGAG   |
| Human   | 18S rRNA | CTTTGGTCGCTGCCTCGT   | CTGCCGGGTTGTTTGTAT    |
| Human   | MANTIS | AAACCTCTGGCTCACAATCCTC | CCGAGACATTCCCTGACATG |
| Mouse   | Anp   | ACCTCCCGAAGCTACCTAAGT | CAACCCCTTCACGCCTCAA   |
| Mouse   | Bnp   | GAGGTACCTCCTATCTGTGGG | GCCATTCTCCCGACTTCTCTC |
| Mouse   | β-Mhc | GAGGTCCTATCCCTATGTTCTG | TTCGCCCTGTAAGCAACTGT |
| Mouse   | Bax   | CCGAAGAGCTGAGGAGGTGT | CAGTCAAGATCATCCTCTCT |
| Mouse   | Bcl2  | TGGGATCTCTTCTCTCCAGC | ACAGTCCTGAGCGACTTCTC |
| Mouse   | GAPDH | ACAAATTTGGCATTTGGA   | GATGCAAGGATGTCTCTG    |
4.3 RNA ChIP assay

Preparation of cell extracts, crosslinking, and isolation of nuclei was performed with the RNA ChIP-IT (Active Motif, USA) according to the manufacturer’s protocol. After sonification of the lysates, cell debris was removed by centrifugation and the supernatant was digested with DNase I. After digestion, the samples were incubated with protein G magnetic beads, BRG1 antibody (IgG as control), and Protease inhibitor over night at 4°C. Elution of the beads was done with elution buffer, and then binding RNA was purified with TRIzol and digested with DNases I. Samples were reverse-transcribed as previously reported (Ge et al., 2014).

**Table 2** Primers for quantitative reverse transcription PCR detection of IncRNA

| Name      | Forward primer (5′−3′)            | Reverse primer (5′−3′)         |
|-----------|-----------------------------------|-------------------------------|
| LincROR   | TATAATGAGATACCCACCTTA             | AGGAACCTGCTATACCGTTTC         |
| THRIL     | AACTCTCGACACTGATGGATCCAT          | AAGGGGTTCAGAAGGTTGCTC         |
| TARID     | CGGTCACACTTCTCTTCAAG              | CTTATGTGAACCAAAAGGCAAC        |
| MEG       | CTCCTCTCTACAGCAGCTCAG             | CTAGCGGCGCTATACCTCTCGGCT      |
| VCAN-AS1-001 | AGACGATTTTCTCCCTTGGTCTT       | TATTGACCTGCTGATGGCA           |
| PANDA     | TGCAACATTTAACCAGGAG               | CCCCAAGCTACATCATGAGCA         |
| ASNCMTRNA2 | ACCCGCGCTACAGCA                  | CGTAAATGATATCATCTACA          |
| PINT      | CCGGCAGCTATCTTCTGTAGT            | AGGAACCCGGAAAGACCTT           |
| MALAT1    | TTATCTTGGAGATAGTTAT              | TAAAGATGCTACATATGG            |
| HEIH      | CCTTCTTGCCCCCTTCTT              | AGGGTCTCAGCCTTTGTCG           |
| HTTAS V1  | GGGCCGCTACGCA                    | GCCAGGACATGCTTCTGATGTT        |
| VAD       | AACTGAAAAACTACATGAAGCA          | CAAAACACCTCTCTCCAC            |
| MIR31HG   | CGGCTTCTGTCCCTCTCAG              | ACAAGCAGACCTTGGAAATG          |
| XIST      | AGTCGCTCTATACGCTGTCC             | ATGCAAACCCGAATATGTC           |
| GAS5      | CGACTCTGTGAGATGTTG              | ATCTCTTTCTGGGAGACCAAC         |
| H19       | CCTCAAGATGAAAAGAATGGTCTA         | TCGAACAGAGAGGACTTAAAGAAGA     |
| 7SL       | GAGTTCTGCTGTGATTGTCGC           | ATCACGAGCGAGATTGAGCA          |
| Gadd7     | GGGAAGCTTGTGAGATGCC             | CACAGCTGCTCCACTCC             |
| HNRNPA1   | AGGAAATTTGGAGGTTGTC             | ATAGGACCATTTGCTGTTG           |
| FAL1      | CCTGCGCAAGAAGCTCATAC           | TAAAGAGACCGACTACTGAGA         |
| MIAT      | TTATCTTACACAGGAGAACAC           | CTCCCTTTTGTGATACCAT           |
| Kcnq1ot1  | ATAGTGATTGGAGACTCTCA           | ACTGTATATTCATGTTTGT           |
| TERRA     | CAGCGAGATTTCTCCAAGCTAAG         | AACCCTACACCAGATGAGACACC       |
| 17A       | CCACTTCGCAAAGCTGACCAT          | GCAAAGGCTGATCCTTGACCTTGG      |
| Lethe     | ACAAATGAGAAGACCTTGGGCC          | ATCGGTCCAGGAGGGCCCA           |
| ANRASSF1  | TTATCCCTCAGCTCTGAC             | CTCCCTTGTGATGCTGCTGCTG        |
| PAPAS     | GCACATCGATACATGCAG             | GCCGACAGGATGCTCAGGCAAGGAG     |
| HOTAIR    | CAGTGAGGAAATCTGACGTCTC          | GTGCCTTCTGCTCTCTTACC          |
| ANRIL     | CTGGGACTAACATGACGCCAC          | GAGGGAGGAGATTGCTCTC           |
| BC200     | AGACGACTCTCTGCTGAGCA           | GTGGGCTGTTGGGAGAAGGATCAG      |
| SALNR     | GATCTAATTTTTCCTCTCTCT           | GAATTTCTGAGAAACAAAC          |
| TERC      | CCCCTTCTCCCTGCTCCTTCACTC        | ACAGAGCCAACTCTCTGCTG          |
| MEG3      | CTCCTGCTCCTCCTCCTCCTCCT         | CTTCTTCTCTCCTCTCCCTCGGACTTC  |
| AS Uch1   | AAACCTACCTTTCCACATTC           | TCTCTATCTTCTAGAGACCCATCAG     |
| BANCR     | TCTTCTGCTGTGACAGGCTGCTG         | GATGGGACCTTTTCTGCTG           |
| PTENp1    | AGTCACCCTTTGAGAAAGCATGACCAA     | CTGCCCCTTACATGACACTGACTTCTTCA|
| HULC      | AATCCTCCAAGACTTGATCCAAATGT     | TCTTCTGCTGATCTGCTGCTG         |
| UCA1      | TGACATTTCTCTGCCAAGATGCTC        | GGGCATATATCATTAAAGTACTTGATGAG|
| BACE1-AS  | GTAGGGAGGAAAGCTAGTACTGA         | AGAGGGTCTGCAGGAGATTC          |
| MANTIS    | GGGTGTTGACTACCTGGAATC          | AAGAGGGAGGAGTCTGCTGAG         |
| TUG1      | CATAGTATATCTTGGGTATAC          | CACAACAACTGAGAGATGTTG         |
| LincRNA-p21 | GGGTGCTACTCTCTGCTGCTG         | TGGCCCTTGGGGGCTTCTGCT         |
4.4 | Scratch wound assays

Human umbilical vein endothelial cells were cultured as a confluent monolayer and scratched with a pipette tip. The cells were incubated with EBM medium and EGM-2 Single Quots. HUVECs were incubated with/without Dioscin. 12 h later, 2 μg/ml of Calcein AM (Invitrogen, USA) was added directly to the well and incubated for 15 min. The images were visualized and captured.

Migration was quantified as the ratio of the area covered with cells to the cell-free area.

4.5 | Transwell assays

Approximately 5 × 10⁴ HUVECs were plated into the upper chamber and were allowed to migrate toward the lower plate (Corning Costar, USA). After 6 h of incubation, HUVECs on the bottom of the Transwell membrane were fixed with 4% paraformaldehyde at 37°C for 20 min and stained with hematoxylin. The membranes were washed three times with PBS and photographed. The migrated cells on the bottom of the surface were counted in eight standardized fields.

4.6 | Matrigel assays (tube formation)

Human umbilical vein endothelial cells in EBM were seeded onto Matrigel (Corning, USA) with Dioscin or negative control. After 8 h of incubation, 2 μg/ml of Calcein AM (Invitrogen, USA) was added directly to the well and incubated for 15 min. The images were visualized and captured. The number of vessel tubes formed was analyzed as described previously (Lu et al., 2016).

4.7 | Real-time RT-PCR assays

Total RNA was isolated from mouse hearts or cultured cells using TRIzol (Invitrogen, USA) according to the manufacturer’s instruction (Li et al., 2019). A total of 0.5 μg of RNA samples were reverse-transcribed using M-MLV Reverse Transcriptase, following the manufacturer’s protocol (Promega, USA). Real-time PCR assay was then performed using the FastStart Universal SYBR Green Master (Roche, Switzerland) and Real-time PCR Detection System (Bio-Rad, USA) as described previously. Experiments were performed in triplicate, and the relative expression levels of the genes were calculated using the 2^(-ΔΔCT) method. The primers used were listed in Table 1 and Table 2.

4.8 | Histological analysis

The fixed hearts were sectioned, and cardiac fibrosis was assessed by staining with Masson’s trichrome. Immunohistochemical staining was performed on paraffin-embedded sections with a primary antibody against CD31 (AF3628, R&D, USA) and BRG1 (SC-17796, Santa, USA) which was followed by incubation with a biotinylated secondary antibody as described previously (Wu et al., 2017).

4.9 | Statistics

All the data were expressed as means ± standard error of the mean (SEM) using GraphPad Prism 8. Two-group comparisons were analyzed by a Student’s t test. For comparisons of more than two groups, one-way ANOVA was employed. Statistical significance is indicated by *p < 0.05.

ACKNOWLEDGEMENTS

We want to thank Dr. Changhan Ouyang for excellent technical assistance, and Dr. Shan Lu for manuscript revise.

CONFLICT OF INTEREST

The authors declare no competing interests.

AUTHOR CONTRIBUTION

QL designed the study. CK, DL, CH, and RL conducted searches, extracted, and analyzed the data. CK and DL wrote the manuscript. All authors contributed to the article and approved the submitted version.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Qiulun Lu https://orcid.org/0000-0002-2565-8816

REFERENCES

Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. *Nature Reviews Cancer*, 8(8), 592–603. https://doi.org/10.1038/nrc2442

Cai, Z., Lu, Q., Ding, Y., Wang, Q., Xiao, L., Song, P., & Zou, M. H. (2015). Endothelial nitric oxide synthase-derived nitric oxide prevents dihydrofolate reductase degradation via promoting S-nitrosylation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 35(11), 2366–2373. https://doi.org/10.1161/ATVBAHA.115.305796

Cremer, S., Michalik, K. M., Fischer, A., Pfisterer, L., Jaé, N., Winter, C., Boon, R. A., Muhly-Reinholz, M., John, D., Uchida, S., Weber, C., Poller, W., Günther, S., Braun, T., Li, D. Y., Maegdefessel, L., Perisic Matic, L., Hedin, U., Soehnlein, O., ... Dimmeler, S. (2019). Hematopoietic deficiency of the long noncoding RNA MALAT1 promotes atherosclerosis and plaque inflammation. *Circulation*, 139(10), 1320–1334. https://doi.org/10.1161/CIRCULAT IONNAHA.117.029015

Del Re, D. P., Amgalan, D., Linkermann, A., Liu, Q., & Kitsis, R. N. (2019). Fundamental mechanisms of regulated cell death and implications for heart disease. *Physiological Reviews*, 99(4), 1765–1817. https://doi.org/10.1152/physrev.00022.2018

Esposito, M. L., Zhang, Y., Qiao, X., Reyelt, L., Paruchuri, V., Schnitzler, G. R., & Kapur, N. K. (2018). Left ventricular unloading before
reperfusion promotes functional recovery after acute myocardial infarction. *Journal of the American College of Cardiology, 72*(5), 501–514. https://doi.org/10.1016/j.jacc.2018.05.034

Fischer, C., Mazzone, M., Jonckx, B., & Carmelletti, P. (2008). FLT1 and its ligands VEGF and PIGF: Drug targets for anti-angiogenic therapy? *Nature Reviews Cancer, 8*(12), 942–956. https://doi.org/10.1038/nrc2524

Ge, D. I., Han, L., Huang, S. Y., Peng, N., Wang, P. C., Jiang, Z., Zhao, J., Su, L. E., Zhang, S. L., Zhang, Y., Kung, H. F., Zhao, B. X., & Miao, J. Y. (2014). Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells. *Autophagy, 10*(6), 957–971. https://doi.org/10.4161/auto.28363

Kaelin, H. G., Chen, M., Tian, F., Tikkanen, J., Ding, L., Andrew Cheung, H. Y., Kaelin, W. G. Jr, Ratcliffe, P. J., & Semenza, G. L. (2016). Pathways for oxygen regulation and homeostasis: The 2016 Albert Lasker basic medical research award. *JAMA, 316*(12), 1252–1253. https://doi.org/10.1001/jama.2016.12386

Khera, A. V., & Kathiresan, S. (2017). Genetics of coronary artery disease: Discovery, biology and clinical translation. *Nature Reviews Genetics, 18*(6), 331–344. https://doi.org/10.1038/nrg.2016.160

Li, J., Gong, L. I., Liu, S., Zhang, Y., Zhang, C., Tian, M. I., Lu, H., Bu, P., Yang, J., Ouyang, C., Jiang, X., Wu, J., Zhang, Y., Min, Q., Zhang, C., & Zhang, W. (2019). Adipose HuR protects against diet-induced obesity and insulin resistance. *Nature Communications, 10*(1), 2375. https://doi.org/10.1038/s41467-019-10348-0

Lin, H., Chen, M., Tian, F., Tikkkanen, J., Ding, L., Andrew Cheung, H. Y., & Liu, M. (2018). Alpha1-Anti-trypsin improves function of porcine donor lungs during ex-vivo lung perfusion. *Journal of Heart and Lung Transplantation, 37*(5), 656–666. https://doi.org/10.1016/j.healun.2017.09.019

Lu, Q., Yao, Y., Hu, Z., Hu, C., Song, Q., Ye, J., Xu, C., Wang, A. Z., Chen, Q., & Wang, Q. K. (2016). Angiogenic factor AGGF1 activates autophagy with an essential role in therapeutic angiogenesis for heart disease. *PLoS Biology, 14*(8), e1002529. https://doi.org/10.1371/journal.pbio.1002529

Michalik, K. M., You, X., Manavski, Y., Doddaballapur, A., Zörnig, M., Braun, T., John, D., Ponomareva, Y., Chen, W., Uchida, S., Boon, R. A., & Dimmelser, S. (2014). Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. *Circulation Research, 114*(9), 1389–1397. https://doi.org/10.1161/CIRCRESAHA.114.303265

Ransohoff, J. D., Wei, Y., & Khavari, P. A. (2018). The functions and unique features of long intergenic non-coding RNA. *Nature Reviews Molecular Cell Biology, 19*(3), 143–157. https://doi.org/10.1038/nrm.2017.104

Rodriguez, F., & Harrington, R. A. (2021). Management of anti-thrombotic therapy after acute coronary syndromes. *New England Journal of Medicine, 384*(5), 452–460. https://doi.org/10.1056/NEJMra1607714

Solo, K., Lavi, S., Kabali, C., Levine, G. N., Kulik, A., John-Baptiste, A. A., Fremes, S. E., Martin, J., Eikelboom, J. W., Ruel, M., Huietema, A. A., Choudhury, T., Bhatt, D. L., Tzemos, N., Mamas, M. A., & Bagur, R. (2019). Anti-thrombotic treatment after coronary artery bypass graft surgery: Systematic review and network meta-analysis. *BMJ, 367*, i5476. https://doi.org/10.1136/bmj.i5476

Tao, X., Sun, X., Yin, L., Han, X. U., Xu, L., Qi, Y., Xu, Y., Li, H., Lin, Y., Liu, K., & Peng, J. (2015). Dioscin ameliorates cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via HMGB-1 inhibition. *Free Radical Biology and Medicine, 84*, 103–115. https://doi.org/10.1016/j.freeradbiomed.2015.03.003

Tao, X., Yin, L., Xu, L., & Peng, J. (2018). Dioscin: A diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections. *Pharmacological Research, 137*, 259–269. https://doi.org/10.1016/j.phrs.2018.09.022

Thiele, H., Akin, I., Sandri, M., de Waha-Thiele, S., Meyer-Saraei, R., Fuernau, G., Eitel, I., Nordbeck, P., Geiser, T., Landmesser, U., Skurk, C., Fach, A., Jobs, A., Lapp, H., Plek, J. J., Noc, M., Gosljar, T., Felix, S. B., Maier, L. S., ... Desch, S. (2018). One-year outcomes after pci strategies in cardiogenic shock. *New England Journal of Medicine, 379*(18), 1699–1710. https://doi.org/10.1056/NEJMoa1808788

van Diepen, S., Katz, J. N., Albert, N. M., Henry, T. D., Jacobs, A. K., Kapur, N. K., Kilic, A., Menon, V., Ohman, E. M., Sweitzer, N. K., Thiele, H., Washam, J. B., & Cohen, M. G. (2017). Contemporary management of cardiogenic shock: A scientific statement from the American heart association. *Circulation, 136*(16), e232–e268. https://doi.org/10.1161/CIR.0000000000000525

Vogel, B., Claessen, B. E., Arnold, S. V., Chan, D., Cohen, D. J., Giannitsis, E., Gibson, C. M., Goto, S., Katus, H. A., Kerneis, M., Kimura, T., Kunadian, V., Pinto, D. S., Shiomi, H., Sperlus, J. A., Steg, P. G., & Mehran, R. (2019). ST-segment elevation myocardial infarction. *Nature Reviews Disease Primers, 5*(1), 39. https://doi.org/10.1038/s41572-019-0090-3

Wu, S., Lu, Q., Wang, Q., Ding, Y. E., Ma, Z., Mao, X., Huang, K., Xie, Z., & Zou, M.-H. (2017). Binding of FUN14 domain containing 1 with inositol 1,4,5-trisphosphate receptor in mitochondriaassociated endoplasmic reticulum membranes maintains mitochondrial dynamics and function in hearts in vivo. *Circulation, 136*(23), 2248–2266. https://doi.org/10.1161/CIRCULATIONAHA.117.030235

Yan, B., Yao, J., Liu, J.-Y., Li, X.-M., Wang, X.-Q., Li, Y.-J., Tao, Z.-F., Song, Y.-C., Chen, Q. I., & Jiang, Q. (2015). IncRNAMiAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. *Circulation Research, 116*(7), 1143–1156. https://doi.org/10.1161/CIRCRESAHA.116.305510

Yao, H., Tao, X., Xu, L., Qi, Y., Yin, L., Han, X. U., Xu, Y., Zheng, L., & Peng, J. (2018). Dioscin alleviates nonalcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway. *Pharmacological Research, 131*, 51–60. https://doi.org/10.1016/j.phrs.2018.03.017

Zampetaki, A., & Mayr, M. (2017). Long noncoding RNAs and angiogenesis: Regulatory information for chromatin remodeling. *Circulation, 136*(1), 80–82. https://doi.org/10.1161/CIRCULATIONAHA.117.028398

Zhang, Y., Xu, Y., Qi, Y., Xu, L., Song, S., Yin, L., Tao, Z., Zhen, Y., Han, X. U., Ma, X., Liu, K., & Peng, J. (2017). Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation. *Toxicology, 378*, 53–64. https://doi.org/10.1016/j.tox.2017.01.007

**How to cite this article:** Kong, C., Lyu, D., He, C., Li, R., & Lu, Q. (2021). Dioscin elevated IncRNA MANTIS in therapeutic angiogenesis for heart diseases. *Aging Cell, 20*, e13392. [https://doi.org/10.1111/ace3.13392](https://doi.org/10.1111/ace3.13392)